A Wall Street high-roller like Ken Griffin did not make it among the big leagues a.k.a. on Forbes’ rich list, without understanding the value in capitalizing on a bull market. Was it a smart third quarter move for Citadel’s CEO and founder to up his stakes significantly in biotech movers and shakers Valeant (NYSE:VRX) and Teva (NYSE:TEVA)?
Story Continues
